Akebia Therapeutics Inc [NASDAQ: AKBA] traded at a high on 2025-07-09, posting a 7.55 gain after which it closed the day’ session at $3.99.
The results of the trading session contributed to over 4696832 shares changing hands. Over the past one week, the price volatility of Akebia Therapeutics Inc stands at 5.43% while the volatility over the past one month is 5.78%.
The market cap for AKBA stock reached $1.05 billion, with 261.64 million shares outstanding and 251.62 million shares in the current float. Compared to the average trading volume of 5.04M shares, AKBA reached a trading volume of 4696832 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Akebia Therapeutics Inc [AKBA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AKBA shares is $7.40 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AKBA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Akebia Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 04, 2025. While these analysts kept the previous recommendation, Leerink Partners raised their target price to Outperform. The new note on the price target was released on April 28, 2025, representing the official price target for Akebia Therapeutics Inc stock. Previously, the target price had yet another raise to $6, while Jefferies analysts kept a Buy rating on AKBA stock.
The Price to Book ratio for the last quarter was 42.47, with the Price to Cash per share for the same quarter was set at 0.43.
How has AKBA stock performed recently?
Akebia Therapeutics Inc [AKBA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.76. With this latest performance, AKBA shares gained by 0.50% in over the last four-week period, additionally plugging by 107.81% over the last 6 months – not to mention a rise of 110.00% in the past year of trading.
Akebia Therapeutics Inc [AKBA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Akebia Therapeutics Inc [AKBA] shares currently have an operating margin of -11.91% and a Gross Margin at 64.95%. Akebia Therapeutics Inc’s Net Margin is presently recorded at -24.51%.
Return on Equity for this stock declined to -16.92%, with Return on Assets sitting at -16.92%.
Insider trade positions for Akebia Therapeutics Inc [AKBA]
There are presently around $38.87%, or 40.31% of AKBA stock, in the hands of institutional investors. The top three institutional holders of AKBA stocks are: BLACKROCK INC. with ownership of 11.64 million shares, which is approximately 5.5499%. VANGUARD GROUP INC, holding 9.28 million shares of the stock with an approximate value of $$9.46 million in AKBA stocks shares; and VANGUARD GROUP INC, currently with $$5.86 million in AKBA stock with ownership which is approximately 2.7409%.
